Department of Health and Human Services May 20, 2009 – Federal Register Recent Federal Regulation Documents

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent Application 60/792,098 entitled ``Tetrahalogenated Compounds Useful as Inhibitors'' [HHS Ref. E-080-2006/0-US-01], PCT Application PCT/US2007/008849 entitled ``Tetrahalogenated Compounds Useful as Inhibitors'' [HHS Ref. E-080-2006/0-PCT-02], Australian Patent Application 2007238785 entitled ``A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties'' [HHS Ref. E-080-2006/0- AU-03], Canadian Patent Application 2,648,216 entitled ``A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties'' [HHS Ref. E-080-2006/0-CA-04], European Patent Application 07755201.6 entitled ``A New Series Of Thalidomide Analogs That Have Potent Anti- angiogenic Properties'' [HHS Ref. E-080-2006/0-EP-05], US Patent Application 12/287,597 entitled ``A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties'' [HHS Ref. E-080-2006/0- US-06], and all continuing patents, patent applications, and foreign counterparts thereto, to CuriRx, Inc., which has offices in Andover, Massachusetts. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America.

The Office of Public Health and Science (OPHS) is seeking nominations of qualified individuals to be considered for appointment as members of the Advisory Committee on Blood Safety and Availability (ACBSA). ACBSA is a Federal advisory committee in the Department of Health and Human Services. Management support for the activities of this Committee is the responsibility of the OPHS.